Integrated BioPharma (INBP) AI Stock Analysis

• Market Cap: $9.16M
• Dividend Yield: N/A
• Average Volume (3M): 10.87K
• Price to Earnings (P/E): 12.1
• Beta (1Y): 0.27
• Revenue Growth: 8.02%
• EPS Growth: 624.32%
• Country: US
• Employees: 147
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): >-0.01
• Shares Outstanding: 31,059,610
• 10 Day Avg. Volume: 10,414
• 30 Day Avg. Volume: 10,872
• PEG Ratio: 0.02
• Price to Book (P/B): 0.53
• Price to Sales (P/S): 0.20
• P/FCF Ratio: 5.77
• Enterprise Value/Market Cap: 0.91
• Enterprise Value/Revenue: 0.15
• Enterprise Value/Gross Profit: 1.50
• Enterprise Value/Ebitda: 2.54
• 1Y Price Target: $0.50
• Price Target Upside: 61.29% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 69 Neutral
• Price Target: $0.50 ▲(61.29% Upside)

Integrated BioPharma's overall stock score is driven by its solid financial performance, characterized by improved revenue growth, profitability, and cash flow generation. The technical analysis supports a positive price trend, while the valuation indicates a reasonable pricing relative to earnings. The absence of earnings call and corporate events data did not impact the score.

Integrated BioPharma Business Overview & Revenue Model

Company Description

Integrated BioPharma (INBP) is a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative healthcare products. The company operates primarily in the pharmaceutical and nutraceutical sectors, offering a diverse portfolio of prescription and over-the-counter medications, dietary supplements, and wellness products. INBP is committed to advancing health through research and development, with a strong emphasis on delivering high-quality, effective solutions for various health conditions.

How the Company Makes Money

Integrated BioPharma generates revenue through multiple streams, primarily by selling its pharmaceutical and nutraceutical products directly to consumers and through partnerships with healthcare providers and distributors. The company's revenue model includes retail sales, online sales, and wholesale distribution. Additionally, INBP may engage in licensing agreements with other pharmaceutical companies for the development and commercialization of specific products, which can provide significant royalties and milestone payments. Strategic collaborations with research institutions and healthcare organizations also contribute to its earnings by enhancing product development and expanding market reach.

Integrated BioPharma Financial Statement Overview

Summary

Integrated BioPharma demonstrates a solid financial performance with improvements in revenue growth, profitability, and cash flow generation. The reduction in leverage and strong equity position enhance financial stability. However, the company needs to focus on further improving net profit margins to enhance overall profitability.

Income Statement

Integrated BioPharma has shown a modest revenue growth rate of 2.7% in the latest year, recovering from previous declines. The gross profit margin improved to 10.23%, indicating better cost management. However, the net profit margin remains low at 1.49%, suggesting challenges in converting revenue into profit. The EBIT and EBITDA margins have improved, reflecting better operational efficiency, but still indicate room for growth.

Balance Sheet

The company's debt-to-equity ratio has improved significantly to 0.05, indicating a strong reduction in leverage and a more stable financial position. Return on equity has increased to 3.98%, showing improved profitability relative to shareholder equity. The equity ratio stands at 81.57%, reflecting a solid capital structure with a high proportion of equity financing.

Cash Flow

Free cash flow growth has been impressive at 99.15%, indicating strong cash generation capabilities. The operating cash flow to net income ratio of 0.49 suggests that the company is generating healthy cash flows relative to its net income. The free cash flow to net income ratio of 0.91 further supports the company's strong cash flow position.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	54.35M	54.35M	50.32M	50.67M	56.25M	63.56M
Gross Profit	5.56M	5.56M	3.88M	4.06M	6.55M	9.48M
EBITDA	3.28M	3.38M	1.54M	1.27M	3.56M	8.33M
Net Income	808.00K	808.00K	112.00K	-34.00K	3.84M	8.01M
Balance Sheet
Total Assets	24.90M	24.90M	26.21M	25.43M	25.25M	25.44M
Cash, Cash Equivalents and Short-Term Investments	3.62M	3.62M	1.68M	1.32M	331.00K	210.00K
Total Debt	1.01M	1.01M	1.80M	2.67M	2.06M	6.00M
Total Liabilities	4.58M	4.58M	6.97M	6.57M	6.67M	11.11M
Stockholders Equity	20.32M	20.32M	19.24M	18.86M	18.57M	14.33M
Cash Flow
Free Cash Flow	1.86M	1.87M	390.00K	1.12M	3.60M	2.75M
Operating Cash Flow	2.06M	2.06M	943.00K	1.23M	4.09M	3.05M
Investing Cash Flow	-205.00K	-205.00K	-553.00K	-111.00K	-465.00K	-199.00K
Financing Cash Flow	78.00K	78.00K	-29.00K	-136.00K	-3.50M	-3.04M

Integrated BioPharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBP, the sentiment is Positive. The current price of 0.31 is above the 20-day moving average (MA) of 0.30, above the 50-day MA of 0.28, and above the 200-day MA of 0.31, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.41 is Neutral, neither overbought nor oversold. The STOCH value of 91.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBP.

Integrated BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FTLF	75 Outperform	$185.00M	24.65	21.88%	―	3.91%	-1.39%
INBP	69 Neutral	$9.16M	12.06	4.09%	―	8.02%	624.32%
NATR	68 Neutral	$257.13M	19.71	9.15%	―	4.33%	-6.33%
USNA	64 Neutral	$370.19M	23.03	6.54%	―	5.92%	―
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
HLF	56 Neutral	$886.71M	2.69	-31.74%	―	-2.25%	288.79%
NAII	42 Neutral	$16.43M	―	-17.98%	―	13.83%	-82.27%

Integrated BioPharma Corporate Events

Integrated BioPharma Secures New Credit Line with PNC

On April 15, 2025, Integrated BioPharma, Inc. and its subsidiary, Manhattan Drug Company, entered into a Loan Agreement with PNC Bank, securing a revolving line of credit of up to $4 million and a Convertible Equipment Line of Credit of up to $500,000. This agreement, which includes a security interest in the company’s assets, aims to support the purchase of equipment and vehicles. Concurrently, Integrated BioPharma and its associated entities settled their previous credit and loan agreement with PNC Bank, paying off the outstanding balance and terminating the prior arrangement, marking a strategic financial restructuring.